Co-Development Deals Are Up 1200% in 2026 — Here's the Data

Twelve co-development deals closed between February and August 2026, up from exactly zero in the prior six-month window — a 1200% increase that marks the sharpest acceleration in shared-risk deal structures we've tracked this year. The catalyst isn't mystery: Big Pharma is staring down patent cliffs, bloated late-stage pipelines, and escalating Phase III costs, and co-development arrangements let two parties split the downside while preserving meaningful upside. This isn't a blip. This is a structural repricing of how pharma does business development.

The Data — Co-Development Deal Activity, Period over Period

The numbers speak for themselves. The prior period was a flatline. The current period is a breakout.

A move from zero to 12 is statistically unusual enough that it warrants scrutiny. But when you look at who's signing these deals — AbbVie, Janssen, AstraZeneca, Merck, Amgen, Novartis, BeiGene — this isn't experimental behavior from mid-caps testing new structures. This is the top tier of global pharma collectively deciding that co-development is the preferred architecture for a specific category of risk.

What's Driving the Trend

Three forces are converging to make co-development licensing in 2026 the default structure for an expanding set of asset types.

First, Phase III economics have become untenable for single-sponsor programs in competitive indications. Oncology and immunology trials routinely exceed $300M in fully loaded costs. When two companies with complementary commercial footprints co-develop an asset, they can cut per-sponsor trial costs by 40–60% while doubling the geographic enrollment capacity. The Amgen-Novartis deal signed July 18 is a textbook example: Amgen brings the molecule and U.S. commercial infrastructure; Novartis brings ex-U.S. reach and oncology trial expertise. Neither party wanted to bear the full Phase III burden alone in a crowded indication.

Second, the patent cliff is forcing urgency. AbbVie's Humira erosion is well-documented, but the broader wave hitting between 2025 and 2028 — covering assets from Keytruda to Opdivo to Stelara — means every major pharma company is simultaneously hunting for pipeline replenishment. Traditional exclusive licensing deals remain available, but co-development structures let buyers access assets faster by offering licensors something more attractive than milestone-heavy waterfalls: shared economics and shared decision-making. The Janssen-AbbVie deal from July 18 is notable precisely because both companies are on the wrong side of major LOE events and chose to pool resources rather than compete for the same external assets.

Third, regulatory dynamics are rewarding co-development. The FDA's increasing comfort with platform trials and adaptive designs means two sponsors can run a single registrational study with shared IND infrastructure. This regulatory tailwind reduces the structural friction that historically made co-development deals harder to execute than clean out-licenses. AstraZeneca and Merck — two companies with deep regulatory affairs teams — signed their co-development agreement on July 20, likely leveraging exactly this kind of shared regulatory pathway.

Notable Deals

The five most significant co-development transactions from this period illustrate the breadth of the trend. These aren't concentrated in one therapeutic area or one deal archetype — they span oncology, immunology, and cross-border structures.

Several patterns are worth flagging. The Pharmacyclics/AbbVie-Janssen deal is a re-engagement between two companies that previously collaborated on ibrutinib — suggesting that co-development relationships, once established, create gravitational pull for future deals. The Amgen-BeiGene transaction underscores the China-plus strategy that more U.S. biotechs are pursuing: BeiGene's APAC clinical trial infrastructure and China commercial presence make it a natural co-development partner for assets that need global registrational data. And the AstraZeneca-Merck pairing is significant because it puts two direct competitors on the same side of a development program — a move that only makes economic sense when both parties believe the indication is large enough to support shared commercial rights without cannibalizing each other.

What's conspicuously absent from this deal set: upfront and total deal value disclosures. Co-development structures inherently resist clean TDV reporting because the economics are split across shared costs, co-promotion revenues, and territory-based royalties rather than traditional milestone waterfalls. BD teams benchmarking these deals should use Deal Benchmarks to compare structural terms rather than headline numbers.

What This Means for BD Teams Right Now

If you're a biotech founder or licensing-out executive sitting on a Phase II asset in a competitive indication, this is a seller's market for co-development structures — but only if you're willing to accept shared control. The data is clear: Big Pharma is actively seeking co-development partners, and 12 deals in six months means multiple BD teams at top-20 pharma companies have internal mandates to execute these structures. Your leverage is highest right now, before this wave normalizes and co-development becomes table stakes rather than a differentiator.

If you're on the buy side, move fast. The concentration of deals in mid-July 2026 suggests a clustering effect — once one major co-development deal closes, it creates internal pressure at competing companies to match. The window for securing preferred partners is narrowing. Waiting until Q4 2026 means competing against more buyers for fewer unpartnered assets.

Structural implications: Traditional exclusive worldwide licenses with milestone-heavy economics are losing ground to co-development frameworks that split costs 50/50 through registration with territory-based commercial splits post-approval. Joint steering committees with equal voting rights are replacing the old licensor-licensee power dynamic. Opt-in/opt-out clauses at Phase III initiation are becoming standard — giving both parties an exit if data disappoints. BD teams that haven't modeled these structures will find themselves at a disadvantage in negotiations. Use Solidus to run scenarios on shared-cost economics before your next term sheet conversation.

One structural trend to watch: co-development deals are increasingly including co-commercialization rights rather than clean territory splits. This means both parties share in the upside across all markets, which aligns incentives but creates complex P&L structures. Finance teams need to be in the room early.

Benchmark your deal against current market rates using the Ambrosia calculator. Co-development deal terms are shifting fast — what was market six months ago is already outdated.